Countries including Indonesia, Brazil, Turkey, and Chile are clamoring for doses of CoronaVac, the vaccine candidate made by Sinovac Biotech. Meanwhile, the maker of another of China’s leading vaccine candidates, Sinopharm, applied last month for market approval.
Five Chinese coronavirus vaccines are in Phase 3 clinical trials, but China has not waited for trials to be complete to inject about one million people since July. Preliminary data suggests that China’s vaccines may be less inoculating than those by Pfizer and Moderna.
Filling yet another void in global leadership left by President Trump, China said that it had joined COVAX, the World Health Organization–backed program to fund and coordinate the equitable global distribution of a COVID-19 vaccine.
China has already vaccinated vast numbers of essential workers and state-owned enterprise employees without a conventional clinical trial process. As soon as this month, however, Beijing may give official approval to a clinically tested vaccine, and begin public rollout in November.
China, under an emergency use authorization, has vaccinated an unspecified number of essential workers outside of clinical trials since July 22, a top health official revealed. At the same time, clinical trials for China’s four COVID-19 vaccine candidates are expanding overseas.
Four vaccines developed by Chinese companies have moved on to Phase 3 trials, accounting for half of the global candidates at that final stage of human testing before approval.
China’s CDC director: ‘Please don’t lose confidence in Chinese-made vaccines’
U.S. health authorities have not received H7N9 avian flu specimens from their Chinese counterparts for more than a year now, according to the New York...
Associated Press reports: Investigators found Changchun Changsheng Life Sciences Ltd. had blended expired fluids in its vaccines and falsified records from as early as April...